Gerard Ged Wallace

Ossyx is a sports medicine company focused on empowering athletes to take control of their treatment. To-date, our products are used by Paris 2024 olympic medallists, world champions, and numerous professional teams.

Cipher Surgical Ltd. is a late stage start-up medical device company commercialising laparoscopic surgery enhancements. My global commercial reputation underpinned the appointment to leverage life sciences, capital raising and pre/post launch oversight capabilities and help secure a successful corporate start-up phase. • Worked with the Board to enhance the business model for tactical implementation and expedite commercial traction, professionally leading an Investment Syndicate to achieve a highly successful funding round.

Acquired by Topcon Healthcare Inc. Toku Eyes harnesses the power of AI to analyse scans from simple eye exams to detect underlying conditions like chronic kidney disease, diabetes and cardiovascular disease, the leading cause of death worldwide. Toku’s AI platforms (BioAge, CLAiR and MyKidneyAI) have been validated on over 4.3 million retinal images, and they read and grades retinal images with gold-standard accuracy and sensitivity. After Series A investments from The US’s National Vision and Japan’s Topcon, the Toku HQ moved to the United States, prior to commercialisation. Initially engaged to advise CEO on capital raising and board member recruitment and structure • Successful Seed and Series A rounds raising $8m • Direct recruitment of consultant Ophthalmology KOL and senior Business consultant in UK and USA • Direct recruitment of globally experienced Board Chairperson • Support for Chief Commercial Officer in securing global partners • Strategy development for novel market access

Ellex manufactures a range of leading-edge ophthalmic laser and imaging devices and the iTrack™ glaucoma surgical system for the diagnosis and treatment of eye disease and fight against blindness. Products are sold through subsidiaries in the United States, Japan, Germany, France and Australia, and via distributors, accessing more than 100 countries. Among the company’s current research efforts is 2RT™ (Retinal Rejuvenation Therapy), a project that is focused on new treatments for diabetic retinopathy and age-related macular degeneration (AMD). In glaucoma treatment, Ellex has novel solutions with its minimally invasive glaucoma surgery (MIGS) devices ( iTrack™ ), and complementary products leading the shift to laser-based intervention as first-line therapy. Manufacturing sites are located in Adelaide, Australia, and Fremont, USA. Sales of approx. $90m, with 290 staff and manufacturing in Australia and USA. Initial focus was on organisational structure, strategy and achieving fiscal year results, in line with market guidance. • Closed fiscal year results within market guidance • Presented Board with organisational, strategic and financial improvement plan for FY 2020 • Commenced reorganisation with globalisation of Operations and Quality leadership, across 2 manufacturing sites • Initiated pricing reviews and identified immediate, significant cash improvement via inventory focus • Review of key distributor markets • Oversaw hiring and integration of new Asian leadership • Completed Investor introduction

The Australian Industry Group (Ai Group) is Australia's peak industry association. It is an Industry Partner for delivering the Australian Government’s Entrepreneurs’ Programme (EP), which offers services and grants to improve SMEs capabilities in e.g. competitiveness, productivity, growth realisation and supply chain management. My Business Adviser focus sector is Medical Technologies and Pharmaceuticals, and the element of EP I drive is Business Management. My consultancy responsibilities include providing formal business evaluations to managing directors of eligible businesses, and subsequently identifying a series of key action plans and strategies for the businesses. I consult with businesses to make those strategies for business improvement happen. Co-funded grants to execute critical components of the plans are available to eligible businesses.

CathRx Ltd. is a start-up medical device company, developing a novel cardiac catheter range for the diagnosis and treatment of cardiac arrhythmias. I spearheaded the commercialization of sustainable catheter products with Clinicians and Procurement in public and private healthcare sectors. I reviewed strategic direction, initiated market and product range analysis, managed clinical evaluation, and input to R&D review. •  Signed agreements with clinical, distribution and manufacturing support entities and conducted catheter evaluations in Europe, securing substantial initial sales via distributors in a test of the market. •  Identified and engaged potential commercial partners in Australasia, Europe, Japan, Middle East and the USA. •  Drove marketing, strategy and route-to-market programs. Directly improved profitability and competitiveness and secured purchase approval from US based procurement agency. •  Attracted financial and technology advisers to the Board and assisted in fundraising initiatives.

Boston Scientific is a global manufacturer & supplier of medical technologies with multi-billion dollar revenues. I decentralised European operations and drove business performance for the Distributor Management Group with additional responsibility as Chairman of BSC International SA (Europe), Guidant Europe, and as a Corporate Operating Committee Member. 1650 staff and revenues of $1.7 Billion. •  Championed a decentralized matrix business model, unifying functional business elements with delegated authority and reporting responsibilities. •  Selected and mentored the senior management team, supporting change programs with the establishment of formalised peer network support programs and a European Operating Committee. •  Maintained market share leadership in BSC legacy business lines and delivered high profitability via substantial revenue growth from underdeveloped Eastern EU and Middle East markets. •  Oversaw post acquisition integration of Guidant and >600 staff. Drove implementation of marketing programs that substantially improved market share of Guidant products.

Baxter International is a multi-billion dollar diversified international healthcare company with global manufacturing facilities. I was appointed to spearhead the revitalization of profitable Asia China regional growth with ten national offices, numerous manufacturing plants and a large workforce. Governance over 12 entities across Asia/China•  Doubled sales, increased cash/profit ratio percentage, and reduced operating expenses as a % of sales . Escalated employee satisfaction levels, streamlined reporting, and enhanced financial control. ROMC improvement by 26% during tenure.  Achieved Regional expansion with new national offices and the acquisition of existing and greenfield manufacturing facilities. Initiated and completed divestiture of an under-performing service business. •  Focused on access and affordability strategies to broaden offerings into emerging markets. •  Initiated creative strategies to increase access to patient treatment funding, treating thousands of dialysis patients and achieving phenomenal annual treated-patient growth across the region.

Specifically promoted to maintain market shares and expand sales growth leveraging large scale of operating expense base across Australia and New Zealand.  Initiated programs that directly impacted top line revenues and bottom line performance, entrepreneurially adding third party distribution services and expanding hospital services.  Relocated NZ staff to new facilities, restructured marketing support and retained and added commercially significant distributorships during a period of change.

I gained earlier senior management experience with Baxter International as General Manager with full P&L and functional responsibility for New Zealand operations.